Why Biotech Startups Are Renting Their R&D Lab Space

Episode 15 of Biotech Business with Fexingo explores the rise of 'lab-as-a-service' — flexible, shared R&D lab spaces that let biotech startups avoid the huge capital costs of building their own facilities. Lucas and Luna dive into the model pioneered by companies like BioLabs and LabCentral, with a focus on a specific case: a 2024 startup that launched a CRISPR screening platform in 60 days using shared lab infrastructure, versus the 18 months it would have taken to build its own. They discuss the economics — saving roughly $2 million in upfront build-out per 1,000 square feet — and the trade-offs: shared equipment queues, data security concerns, and the risk of losing the proprietary culture that comes with a dedicated lab. The hosts also touch on how the model is evolving: the first lab-as-a-service REITs are now trading on the NASDAQ, and big pharma is starting to rent adjacent benches to stay close to innovation. A useful episode for anyone building in biotech or thinking about capital efficiency in science. #LabAsAService #BiotechInfrastructure #StartupCapitalEfficiency #BioLabs #LabCentral #SharedLabSpace #CRISPR #DrugDiscovery #RDBiotech #LifeSciences #RealEstate #REIT #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness #Podcast Keep every episode free: buymeacoffee.com/fexingo